Early-stage Potential Stellate Therapeutics is a pre-clinical biotech startup focused on microbiome-derived small molecules for neurodegenerative diseases, presenting an opportunity to engage on early strategic partnerships, research collaborations, and pilot programs to shape the development pathway for their lead Parkinson’s candidate.

Niche Gut‑Brain Axis The company emphasizes the gut-brain axis and microbiome metabolites, suggesting sales opportunities in specialized CROs, translational research services, and platform collaborations that align with their mechanistic focus and accelerate preclinical milestones.

Lean Operations With a small team and revenue under a million, Stellate represents a budget-conscious partner open to cost-effective collaborations, grants support, and co-development models that minimize upfront risk while advancing compound discovery and early-stage validation.

Technology Stack Fit Their reliance on standard web tech hints at a modern digital presence and potential interest in technology-enabled partnerships, data management platforms, or digital marketing services to support investor outreach and external collaboration.

Limited Scale, Big Upside As a two-to-ten person organization with a Parkinson’s focus, there is a clear opportunity to position high-touch, high-value collaborations with large pharma players seeking early-stage innovation in neuroscience and microbiome therapeutics.